JDRF and Tandem Diabetes Care Partner to Help Educate and Support the T1D Community
San Diego, CA – July 8, 2020 – JDRF, the leading global organization funding type 1 diabetes (T1D) research, and Tandem Diabetes Care (NASDAQ: TNDM), a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience, announce a new national partnership to help drive awareness and education on topics related to technology innovation, diabetes management, and healthcare for people with diabetes.
The partnership will utilize JDRF’s community facing platforms, including local chapter events, digital channels, and education programs to bring to life the benefits of devices such as insulin pumps, continuous glucose monitors and novel treatment approaches like hybrid closed loop therapy.
“Together, we will show how innovations in type 1 diabetes management and care will continue to minimize the intrusions of T1D on day-to-day life and provide better health outcomes for people living with the disease,” said Joe Watterson, JDRF Vice President of Corporate Development.
People living with T1D have a variety of needs that span from reducing the daily burden of disease management to finding a trusted technology partner who can deliver solutions that work reliably, provide clinical benefits, and improve their overall quality of life. The JDRF and Tandem partnership aims to actively support the growing needs of the T1D community and help address the gap in diabetes education on these topics through regional and local activities, including select Type One Nation Summits and JDRF One Walk events.
“Education is the foundation for improved quality of life and clinical outcomes for people with type 1 diabetes, and we are proud to partner with JDRF in furthering our shared mission to support the diabetes community,” said Brian Hansen, Executive Vice President and Chief Commercial Officer at Tandem Diabetes Care.
JDRF Contact Information:
Ayana Young, 347-496-2494, firstname.lastname@example.org
Tandem Diabetes Care Contact Information:
Media: Steve Sabicer, 714-907-6264, email@example.com
Investors: Susan Morrison, 858-366-6900 x7005, IR@tandemdiabetes.com
JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.2 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our six international affiliates are dedicated to advocacy, community engagement and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter: @JDRF
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2, and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.